Related Experiment Video
Updated: Jan 6, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Machine Learning-Based Detection of EGFR Mutation and HER2 Overexpression in Metastatic Brain Adenocarcinoma:
Mohammad Sadra Gholami Chahkand1, Mohammad Amin Karimi2, Komeil Aghazadeh-Habashi3
1Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran.
Background And Aim:
Brain metastases (BMs) are the most common intracranial malignancy, often arising from lung, breast, and melanoma cancers. Receptor tyrosine kinases, such as EGFR and HER2, drive tumor progression and resistance to therapy. Noninvasive detection of these biomarkers, especially in brain metastases, is crucial due to challenges with traditional biopsy methods. This systematic review and meta-analysis assess machine learning (ML)-based models for detecting EGFR mutations and HER2 overexpression in metastatic brain adenocarcinoma using MRI-derived radiomic features.
Methods:
A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. Studies were identified via PubMed, Scopus, and Web of Science, focusing on ML applications to MRI radiomics for detecting EGFR and HER2 in brain metastases. Data on study design, imaging modality, model type, sample size, and performance metrics were extracted. Subgroup analyses were performed by model type (deep learning vs. classical ML) and sample size (<150 vs. ≥150 participants). A random-effects model was used to pool performance metrics, and risk of bias was assessed using the RoB 2 tool. STATA version 18 and Python 3.10 were used for analyses and visualizations.
Results:
Of 383 identified studies, 31 (7925 participants) met the inclusion criteria. The pooled analysis showed strong diagnostic performance: AUC = 0.84, accuracy = 0.86, and sensitivity = 0.83. Subgroup analysis revealed higher AUC and accuracy in deep learning models compared with classical ML. Sensitivity analysis also indicated improved AUC in studies with larger sample sizes (≥150), though variability remained. No evidence of heterogeneity or publication bias was detected.
Conclusion:
ML models demonstrate strong diagnostic performance for detecting EGFR and HER2 in metastatic brain adenocarcinoma, supporting their potential as noninvasive diagnostic tools. However, these findings should be interpreted considering methodological heterogeneity and the limited use of external validation. Further prospective, multicenter studies are warranted to confirm their clinical applicability and generalizability.
